Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer

BACKGROUND: We conducted a Phase 1 study to evaluate safety and activity of olaparib tablets and oral cyclophosphamide. METHODS: Patients had metastatic breast cancer (BC) or recurrent high-grade serous ovarian cancer (HGSOC), performance status 0–2, and ≤3 lines of prior therapy. Patients were trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chee Khoon, Scott, Clare, Lindeman, Geoffrey J., Hamilton, Anne, Lieschke, Elizabeth, Gibbs, Emma, Asher, Rebecca, Badger, Heath, Paterson, Robin, Macnab, Lauren, Kwan, Edmond Michael, Francis, Prudence A., Boyle, Frances, Friedlander, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353881/
https://www.ncbi.nlm.nih.gov/pubmed/30655615
http://dx.doi.org/10.1038/s41416-018-0349-6

Ejemplares similares

Ejemplares similares